425 related articles for article (PubMed ID: 34591258)
1. A Decade of Fighting Invasive Meningococcal Disease: A Narrative Review of Clinical and Real-World Experience with the MenACWY-CRM Conjugate Vaccine.
Ruiz Garcia Y; Abitbol V; Pellegrini M; Bekkat-Berkani R; Soumahoro L
Infect Dis Ther; 2022 Apr; 11(2):639-655. PubMed ID: 34591258
[TBL] [Abstract][Full Text] [Related]
2. Immunogenicity and safety of a pentavalent meningococcal ABCWY vaccine in adolescents and young adults: an observer-blind, active-controlled, randomised trial.
Peterson J; Drazan D; Czajka H; Maguire J; Pregaldien JL; Seppa I; Maansson R; O'Neill R; Balmer P; Jodar L; Jansen KU; Anderson AS; Perez JL; Beeslaar J
Lancet Infect Dis; 2023 Dec; 23(12):1370-1382. PubMed ID: 37579773
[TBL] [Abstract][Full Text] [Related]
3. Modeling the public health impact of different meningococcal vaccination strategies with 4CMenB and MenACWY versus the current toddler MenACWY National Immunization Program in Chile.
Graña MG; Cavada G; Vasquez M; Shen J; Maervoet J; Klint J; Gómez JA
Hum Vaccin Immunother; 2021 Dec; 17(12):5603-5613. PubMed ID: 34890520
[TBL] [Abstract][Full Text] [Related]
4. Immunogenicity and safety of the 4CMenB and MenACWY-CRM meningococcal vaccines administered concomitantly in infants: A phase 3b, randomized controlled trial.
Macias Parra M; Gentile A; Vazquez Narvaez JA; Capdevila A; Minguez A; Carrascal M; Willemsen A; Bhusal C; Toneatto D
Vaccine; 2018 Nov; 36(50):7609-7617. PubMed ID: 30414782
[TBL] [Abstract][Full Text] [Related]
5. Safety of a quadrivalent meningococcal serogroups A, C, W and Y conjugate vaccine (MenACWY-CRM) administered with routine infant vaccinations: results of an open-label, randomized, phase 3b controlled study in healthy infants.
Abdelnour A; Silas PE; Lamas MR; Aragón CF; Chiu NC; Chiu CH; Acuña TH; Castrejón Tde L; Izu A; Odrljin T; Smolenov I; Hohenboken M; Dull PM
Vaccine; 2014 Feb; 32(8):965-72. PubMed ID: 24397906
[TBL] [Abstract][Full Text] [Related]
6. An update of clinical experience with the quadrivalent meningococcal ACWY-CRM conjugate vaccine.
Keshavan P; Pellegrini M; Vadivelu-Pechai K; Nissen M
Expert Rev Vaccines; 2018 Oct; 17(10):865-880. PubMed ID: 30198805
[TBL] [Abstract][Full Text] [Related]
7. Immunogenicity and safety of a quadrivalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine (MenACWY-TT) administered to adults aged 56 Years and older: results of an open-label, randomized, controlled trial.
Dbaibo G; El-Ayoubi N; Ghanem S; Hajar F; Bianco V; Miller JM; Mesaros N
Drugs Aging; 2013 May; 30(5):309-19. PubMed ID: 23494214
[TBL] [Abstract][Full Text] [Related]
8. Effect of a quadrivalent meningococcal ACWY glycoconjugate or a serogroup B meningococcal vaccine on meningococcal carriage: an observer-blind, phase 3 randomised clinical trial.
Read RC; Baxter D; Chadwick DR; Faust SN; Finn A; Gordon SB; Heath PT; Lewis DJ; Pollard AJ; Turner DP; Bazaz R; Ganguli A; Havelock T; Neal KR; Okike IO; Morales-Aza B; Patel K; Snape MD; Williams J; Gilchrist S; Gray SJ; Maiden MC; Toneatto D; Wang H; McCarthy M; Dull PM; Borrow R
Lancet; 2014 Dec; 384(9960):2123-31. PubMed ID: 25145775
[TBL] [Abstract][Full Text] [Related]
9. Antibody persistence and booster response of a quadrivalent meningococcal conjugate vaccine in adolescents.
Baxter R; Reisinger K; Block SL; Izu A; Odrljin T; Dull P
J Pediatr; 2014 Jun; 164(6):1409-15.e4. PubMed ID: 24657122
[TBL] [Abstract][Full Text] [Related]
10. Phase III comparison of an investigational quadrivalent meningococcal conjugate vaccine with the licensed meningococcal ACWY conjugate vaccine in adolescents.
Jackson LA; Baxter R; Reisinger K; Karsten A; Shah J; Bedell L; Dull PM;
Clin Infect Dis; 2009 Jul; 49(1):e1-10. PubMed ID: 19476428
[TBL] [Abstract][Full Text] [Related]
11. Immunogenicity and safety of the quadrivalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine (MenACWY-TT) in 2-10-year-old children: results of an open, randomised, controlled study.
Knuf M; Romain O; Kindler K; Walther U; Tran PM; Pankow-Culot H; Fischbach T; Kieninger-Baum D; Bianco V; Baine Y; Miller J
Eur J Pediatr; 2013 May; 172(5):601-12. PubMed ID: 23307281
[TBL] [Abstract][Full Text] [Related]
12. 'Be on the TEAM' Study (Teenagers Against Meningitis): protocol for a controlled clinical trial evaluating the impact of 4CMenB or MenB-fHbp vaccination on the pharyngeal carriage of meningococci in adolescents.
Carr J; Plested E; Aley P; Camara S; Davis K; MacLennan JM; Gray S; Faust SN; Borrow R; Christensen H; Trotter C; Maiden MCJ; Finn A; Snape MD;
BMJ Open; 2020 Oct; 10(10):e037358. PubMed ID: 33093030
[TBL] [Abstract][Full Text] [Related]
13. Public health perspective of a pentavalent meningococcal vaccine combining antigens of MenACWY-CRM and 4CMenB.
Bekkat-Berkani R; Fragapane E; Preiss S; Rappuoli R; Sohn WY; Soumahoro L; Vadivelu K
J Infect; 2022 Nov; 85(5):481-491. PubMed ID: 36087745
[TBL] [Abstract][Full Text] [Related]
14. Quadrivalent meningococcal tetanus toxoid-conjugate booster vaccination in adolescents and adults: phase III randomized study.
Zambrano B; Peterson J; Deseda C; Julien K; Spiegel CA; Seyler C; Simon M; Hoki R; Anderson M; Brabec B; Áñez G; Shi J; Pan J; Hagenbach A; Von Barbier D; Varghese K; Jordanov E; Dhingra MS
Pediatr Res; 2023 Sep; 94(3):1035-1043. PubMed ID: 36899125
[TBL] [Abstract][Full Text] [Related]
15. A phase III observer-blind randomized, controlled study to evaluate the immune response and the correlation with nasopharyngeal carriage after immunization of university students with a quadrivalent meningococcal ACWY glycoconjugate or serogroup B meningococcal vaccine.
Read RC; Dull P; Bai X; Nolan K; Findlow J; Bazaz R; Kleinschmidt A; McCarthy M; Wang H; Toneatto D; Borrow R
Vaccine; 2017 Jan; 35(3):427-434. PubMed ID: 27912986
[TBL] [Abstract][Full Text] [Related]
16. Immunogenicity and safety of a novel quadrivalent meningococcal conjugate vaccine (MenACWY-CRM) in healthy Korean adolescents and adults.
Lee HJ; Chung MH; Kim WJ; Hong YJ; Choi KM; Lee J; Oh CE; Welsch JA; Kim KH; Hong KB; Dagnew AF; Bock H; Dull PM; Odrljin T
Int J Infect Dis; 2014 Nov; 28():204-10. PubMed ID: 25316331
[TBL] [Abstract][Full Text] [Related]
17. Antibody persistence and booster response following MenACWY-CRM vaccination in children as assessed by two different assay methods.
Klein NP; Block SL; Essink B; Barbi S; Smolenov I; Keshavan P
Vaccine; 2019 Jul; 37(32):4460-4467. PubMed ID: 31279564
[TBL] [Abstract][Full Text] [Related]
18. Immunogenicity and safety of a multicomponent meningococcal serogroup B vaccine and a quadrivalent meningococcal CRM197 conjugate vaccine against serogroups A, C, W-135, and Y in adults who are at increased risk for occupational exposure to meningococcal isolates.
Kimura A; Toneatto D; Kleinschmidt A; Wang H; Dull P
Clin Vaccine Immunol; 2011 Mar; 18(3):483-6. PubMed ID: 21177912
[TBL] [Abstract][Full Text] [Related]
19. MenACWY-CRM conjugate vaccine booster dose given 4-6 years after priming: Results from a phase IIIb, multicenter, open label study in adolescents and adults.
Tipton M; Daly W; Senders S; Block SL; Lattanzi M; Mzolo T; Barbi S; Pellegrini M; Keshavan P
Vaccine; 2019 Sep; 37(42):6171-6179. PubMed ID: 31495595
[TBL] [Abstract][Full Text] [Related]
20. Quadrivalent meningococcal vaccination of adults: phase III comparison of an investigational conjugate vaccine, MenACWY-CRM, with the licensed vaccine, Menactra.
Reisinger KS; Baxter R; Block SL; Shah J; Bedell L; Dull PM
Clin Vaccine Immunol; 2009 Dec; 16(12):1810-5. PubMed ID: 19812260
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]